Bahrain authorises emergency use of REGN-COV2 for treatment of COVID-19

Bahrain’s National Health Regulatory Authority (NHRA) has approved REGN-COV2 for emergency use, a new drug by Regeneron in collaboration with F. Hoffmann-La Roche, for the treatment of mild to moderate COVID-19 cases.

REGN-COV2 contains a combination of Casirivimab and Imdevimab, which are monoclonal antibodies, designed to block viral attachment and entry into human cells to neutralise the virus.

The drug has been added to the list of approved drugs by the Kingdom of Bahrain for treatment of COVID-19 using antibody testing technology.



Related Articles

Back to top button